Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders (original) (raw)

• George, S. R., O'Dowd, B. F. & Lee, S. P. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nature Rev. Drug Discov. 1, 808–820 (2002).
  CAS Google Scholar
• Spiegel, A. M. Mutations in G proteins and G protein-coupled receptors in endocrine disease. J. Clin. Endocrinol. Metab. 81, 2434–2442 (1996).
  CAS PubMed Google Scholar
• Rana, B. K., Shiina, T. & Insel, P. A. Genetic variations and polymorphisms of G protein-coupled receptors: functional and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 41, 593–624 (2001).
  CAS PubMed Google Scholar
• Howard, A. D. et al. Orphan G-protein-coupled receptors and natural ligand discovery. Trends Pharmacol. Sci. 22, 132–140 (2001).
  CAS PubMed Google Scholar
• Mohler, H. F., Fritschy, J. M. & Rudolph, U. A new benzodiazepine pharmacology. J. Pharmacol. Exp. Ther. 300, 2–8 (2002).
  CAS PubMed Google Scholar
• Langmead, C. J. & Christopoulos, A. Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. Trends Pharmacol. Sci. 27, 475–481 (2006).
  CAS PubMed Google Scholar
• May, L. T., Leach, K., Sexton, P. M. & Christopoulos, A. Allosteric modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 47, 1–51 (2007). Comprehensive overview of principles, mechanisms and examples of GPCR allosterism.
  CAS PubMed Google Scholar
• Lazareno, S. & Birdsall, N. J. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol. Pharmacol. 48, 362–378 (1995).
  CAS PubMed Google Scholar
• Ehlert, F. J. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol. Pharmacol. 33, 187–194 (1988).
  CAS PubMed Google Scholar
• Hall, D. A. Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol. Pharmacol. 58, 1412–1423 (2000). Together with reference 9, important theoretical papers describing the application and extension of the ternary complex model to allosteric interactions.
  CAS PubMed Google Scholar
• Christopoulos, A. & Kenakin, T. G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54, 323–374 (2002).
  CAS PubMed Google Scholar
• Christopoulos, A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nature Rev. Drug Discov. 1, 198–210 (2002).
  CAS Google Scholar
• Lazareno, S., Dolezal, V., Popham, A. & Birdsall, N. J. Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol. Pharmacol. 65, 257–266 (2004).
  CAS PubMed Google Scholar
• Valant, C. et al. A novel mechanism of G protein-coupled receptor functional selectivity: Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J. Biol. Chem. (2008). Discovery and validation of a bitopic orthosteric/allosteric mode of action of a functionally selective GPCR ligand.
• Kenakin, T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nature Rev. Drug Discov. 4, 919–927 (2005).
  CAS Google Scholar
• Urban, J. D. et al. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320, 1–13 (2007).
  CAS PubMed Google Scholar
• Mathiesen, J. M. et al. Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2. Mol. Pharmacol. 68, 393–402 (2005). One of the earliest and most striking examples of allosteric modulator-mediated stimulus trafficking.
  CAS PubMed Google Scholar
• Zhang, Y., Rodriguez, A. L. & Conn, P. J. Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. J. Pharmacol. Exp. Ther. 315, 1212–1219 (2005).
  CAS PubMed Google Scholar
• Leach, K., Sexton, P. M. & Christopoulos, A. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol. Sci. 28, 382–389 (2007).
  CAS PubMed Google Scholar
• May, L. T. & Christopoulos, A. Allosteric modulators of G-protein-coupled receptors. Curr. Opin. Pharmacol. 3, 551–556 (2003).
  CAS PubMed Google Scholar
• Harrington, P. E. & Fotsch, C. Calcium sensing receptor activators: calcimimetics. Curr. Med. Chem. 14, 3027–3034 (2007).
  CAS PubMed Google Scholar
• Dorr, P. et al. Maraviroc (UK-427, 857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49, 4721–4732 (2005).
  CAS PubMed PubMed Central Google Scholar
• Kola, I. & Landis, J. Can the pharmaceutical industry reduce attrition rates? Nature Rev. Drug Discov. 3, 711–715 (2004).
  CAS Google Scholar
• Conn, P. J. & Pin, J. P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37, 205–237 (1997).
  CAS PubMed Google Scholar
• Romano, C., Sesma, M. A., Mcdonald, C. T., O'Malley, K., Van den Pol., A. N. & Olney, J. W. Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J. Comp. Neurol. 355, 455–469 (1995).
  CAS PubMed Google Scholar
• Valenti, O., Conn, P. J. & Marino, M. J. Distinct physiological roles of the Gq-coupled metabotropic glutamate receptors Co-expressed in the same neuronal populations. J. Cell Physiol. 191, 125–137 (2002).
  CAS PubMed Google Scholar
• Annoura, H., Fukunaga, A., Uesugi, M., Tatsouka, T. & Horikawa, Y. A novel class of antagonists for metabotropic glutamate receptors, 7-(hydroxyimino)cyclopropchromen-1acarboxylates. Bioorg Med. Chem. Lett. 6, 763–766 (1996).
  CAS Google Scholar
• Varney, M. A. et al. SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J. Pharmacol. Exp. Ther. 290, 170–181 (1999). Together with reference 27, seminal papers reporting the discovery of early, novel GPCR negative allosteric modulators (NAMS) for metabotropic glutamate receptors.
  CAS PubMed Google Scholar
• Gasparini, F. et al. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38, 1493–1503 (1999).
  CAS PubMed Google Scholar
• Cosford, N. D. et al. 3-[(2-Methyl-1, 3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J. Med. Chem. 46, 204–206 (2003).
  CAS PubMed Google Scholar
• Lea, P. M. & Faden, A. I. Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP. CNS Drug Rev. 12, 149–166 (2006).
  CAS PubMed PubMed Central Google Scholar
• Yu, M. Recent developments of the PET imaging agents for metabotropic glutamate receptor subtype 5. Curr. Top. Med. Chem. 7, 1800–1805 (2007).
  CAS PubMed Google Scholar
• Swanson, C. J. et al. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nature Rev. Drug Discov. 4, 131–144 (2005).
  CAS Google Scholar
• Porter, R. H. et al. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J. Pharmacol. Exp. Ther. 315, 711–721 (2005).
  CAS PubMed Google Scholar
• Patel, J. B., Martin, C. & Malick, J. B. Differential antagonism of the anticonflict effects of typical and atypical anxiolytics. Eur. J. Pharmacol. 86, 295–298 (1982).
  CAS PubMed Google Scholar
• Pecknold, J. C., McClure, D. J., Appeltauer, L., Wrzesinski, L. & Allan, T. Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J. Clin. Psychopharmacol. 2, 129–133 (1982).
  CAS PubMed Google Scholar
• Bear, M. F., Huber, K. M., Warren, S. T. The mGluR theory of fragile X mental retardation. Trends Neurosci. 27, 370–377 (2004).
  CAS PubMed Google Scholar
• Slassi, A. et al. Recent advances in non-competitive mGlu5 receptor antagonists and their potential therapeutic applications. Curr. Top. Med. Chem. 5, 897–911 (2005).
  CAS PubMed Google Scholar
• Kinney, G. G., Burno, M., Campbell, U. C., Hernandez, L. M., Rodriguez, D., Bristow, L. J. & Conn, P. J. Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J. Pharmacol. Exp. Ther. 306, 116–123 (2003).
  CAS PubMed Google Scholar
• Campbell, U. C., Lalwani, K., Hernandez, L., Kinney, G. G., Conn, P. J. & Bristow, L. J. The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats. Psychopharmacology (Berl.) 175, 310–318 (2004).
  CAS Google Scholar
• Rodriguez, A. et al. A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators. Mol. Pharmacol. 68, 1793–1802 (2005). This study reports the initial discovery of a GPCR NAM that has partial antagonist activity as well as being a novel, neutral allosteric-site ligand.
  CAS PubMed Google Scholar
• Marino, M. J. & Conn, P. J. Direct and indirect modulation of the N-methyl D-aspartate receptor. Curr. Drug Target CNS Neurol. Disord. 1, 1–16 (2002).
  CAS Google Scholar
• Moghaddam, B. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (Berl.) 174, 39–44 (2004).
  CAS Google Scholar
• Alagarsamy, S., Sorensen, S. D. & Conn, P. J. Coordinate regulation of metabotropic glutamate receptors. Curr. Opin. Neurobiol. 11, 357–362 (2001).
  CAS PubMed Google Scholar
• Mannaioni, G., Marino, M. J., Valenti, O., Traynelis, S. F. & Conn, P. J. Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function. J. Neurosci. 21, 5925–5934 (2001).
  CAS PubMed PubMed Central Google Scholar
• Lindsley, C. W. et al. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr. Top. Med. Chem. 6, 771–785 (2006).
  CAS PubMed Google Scholar
• Alagarsamy, S., Marino, M. J., Rouse, S. T., Gereau, R. W., Heinemann, S. F. & Conn, P. J. Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems. Nature Neurosci. 2, 234–240 (1999a).
  CAS PubMed Google Scholar
• O'Brien, J. A. et al. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol. Pharmacol. 64, 731–740 (2003). Initial discovery of mGluR5-positive allosteric modulators (PAMs) and demonstration that compounds in a single structural class can have PAM, NAM and neutral allosteric site activity.
  CAS PubMed Google Scholar
• O'Brien, J. A. et al. A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J. Pharmacol. Exp. Ther. 309, 568–577 (2004).
  CAS PubMed Google Scholar
• Lindsley, C. W. et al. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1, 3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo. J. Med. Chem. 47, 5825–5828 (2004).
  CAS PubMed Google Scholar
• Kinney, G. G. et al. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J. Pharmacol. Exp. Ther. 313, 199–206 (2005).
  CAS PubMed Google Scholar
• Zhao, Z. et al. Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA. Bioorg Med. Chem. Lett. 17, 1386–1391 (2007).
  CAS PubMed Google Scholar
• Chen, Y. et al. Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses. Mol. Pharmacol. 71, 1389–1398 (2007).
  CAS PubMed Google Scholar
• Chen, Y., Goudet, C., Pin, J. P. & Conn, P. J. N-{4-Chloro-2-[(1, 3-dioxo-1, 3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors. Mol. Pharmacol. 73, 909–18 (2008).
  CAS PubMed Google Scholar
• de Paulis, T. et al. Substituent effects of N-(1, 3-diphenyl-1 H-pyrazol-5-yl) benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes. J. Med. Chem. 49, 3332–3344 (2006).
  CAS PubMed Google Scholar
• Epping-Jordan, M. P. et al. In vivo characterization of mGluR5 positive allosteric modulators as novel treatments for schizophrenia and cognitive dysfunction. Neuropharmacol. 49, 243 (2005).
  Google Scholar
• Darrah, J. M., Stefani, M. R. & Moghaddam, B. Interaction of N-methyl-D-aspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm. Behav. Pharmacol. 19, 225–234 (2008).
  CAS PubMed PubMed Central Google Scholar
• Schoepp, D. D., Wright, R. A., Levine, L. R., Gaydos, B. & Potter, W. Z. LY354740, an mGlu2/3 receptor agonist as a novel approach to trat anxiety/stress. Stress 6, 189–197 (2003).
  CAS PubMed Google Scholar
• Swanson, C. J., Bures, M., Johnson, M. P., Linden, A. M., Monn, J. A. & Schoepp, D. D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nature Rev. Drug Discov. 4, 131–144 (2005).
  CAS Google Scholar
• Schoepp, D. D. & Marek, G. J. Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia? Curr. Drug Target CNS Neurol. Disord. 1, 215–225 (2002).
  CAS Google Scholar
• Conn, P. J., Tamminga, C., Schoepp, D. D. & Lindsley, C. Schizophrenia: moving beyond monoamine antagonists. Mol. Interv 8, 99–107 (2008b).
• Grillon, C., Cordova, J., Levine, L. R. & Morgan, C. A. 3rd. Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology (Berl.) 168, 446–454 (2003).
  CAS Google Scholar
• Patil, S. T. et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nature Med. 13, 1102–1107 (2007).
  CAS PubMed Google Scholar
• Fell, M. J., Svensson, K. A., Johnson, B. G. & Schoepp, D. D. Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (−)-(1R, 4S, 5S, 6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4, 6-dicarboxylic acid (LY404039). J. Pharmacol. Exp. Ther. 326, 209–217 (2008).
  CAS PubMed Google Scholar
• Galici, R., Echemendia, N. G., Rodriguez, A. L. & Conn, P. J. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J. Pharmacol. Exp. Ther. 315, 1181–1187 (2005).
  CAS PubMed Google Scholar
• Johnson, M. P. et al. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2, 2, 2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine. J. Med. Chem. 46, 3189–3192 (2003).
  CAS PubMed Google Scholar
• Lorrain, D. S. et al. Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge. Neuropsychopharmacology 28, 1622–1632 (2003).
  CAS PubMed Google Scholar
• Schaffhauser, H. et al. Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol. Pharmacol. 64, 798–810 (2003).
  CAS PubMed Google Scholar
• Pinkerton, A. B. et al. Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 3: Identification and biological activity of indanone containing mGlu2 receptor potentiators. Bioorg Med. Chem. Lett. 15, 1565–1571 (2005).
  CAS PubMed Google Scholar
• Cube, R. V. et al. 3-(2-Ethoxy-4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy}phenyl)propanoic acid: a brain penetrant allosteric potentiator at the metabotropic glutamate receptor 2 (mGluR2). Bioorg Med. Chem. Lett. 15, 2389–2393 (2005).
  CAS PubMed Google Scholar
• Galici, R. et al. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J. Pharmacol. Exp. Ther. 318, 173–185 (2006).
  CAS PubMed Google Scholar
• Rowe, B. A. et al. Transposition of three amino acids transforms the human metabotropic glutamate receptor (mGluR)-3 positive allosteric modulation site to mGluR2, and additional characterization of the mGluR2 positive allosteric modulation Site. J. Pharmacol. Exp. Ther. Apr 22 2008 (epub ahead of print).
• Poisik, O. et al. Metabotropic glutamate receptor 2 modulates excitatory synaptic transmission in the rat globus pallidus. Neuropharmacology 49, 135–145 (2005).
  Google Scholar
• Bennyworth, M. et al. A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol. Pharmacol. 72, 477–484 (2007).
  Google Scholar
• Lorrain, D. S., Baccei, C. S., Bristow, L. J., Anderson, J. J. & Varney, M. A. Effects of ketamine and _N_-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117, 697–706 (2003a).
• Moghaddam, B. & Adams, B. W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281, 1349–1352 (1998).
  CAS PubMed Google Scholar
• Marek, G. J., Wright, R. A., Schoepp, D. D., Monn, J. A. & Aghajanian, G. K. Physiological antagonism between 5-hydroxytryptamine(2A) and group II metabotropic glutamate receptors in prefrontal cortex. J. Pharmacol. Exp. Ther. 292, 76–87 (2000).
  CAS PubMed Google Scholar
• Johnson, M. P. et al. Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology (Berl.) 179, 271–283 (2005).
  CAS Google Scholar
• Govek, S. P. et al. Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGluR2): efficacy in an animal model for schizophrenia. Bioorg Med. Chem. Lett. 15, 4068–4072 (2005).
  CAS PubMed Google Scholar
• Conn, P. J., Battaglia, G., Marino, M. J. & Nicoletti, F. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nature Rev. Neurosci. 6, 787–798 (2005).
  CAS Google Scholar
• Poewe, W. H., Lees, A. J. & Stern, G. M. Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations. Clin. Neuropharmacol. 9, 430–439 (1986).
  CAS PubMed Google Scholar
• Wichmann, T. & DeLong, M. R. Functional neuroanatomy of the basal ganglia in Parkinson's disease. Adv. Neurol. 91, 9–18 (2003).
  PubMed Google Scholar
• Bradley, S. R. et al. Activation of group II metabotropic glutamate receptors inhibits synaptic excitation of the substantia Nigra pars reticulata. J. Neurosci. 20, 3085–3094 (2000).
  CAS PubMed PubMed Central Google Scholar
• Valenti, O. et al. Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse. J. Neurosci. 23, 7218–7226 (2003).
  CAS PubMed PubMed Central Google Scholar
• Lopez, S. et al. Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease. J. Neurosci. 27, 6701–6711 (2007).
  CAS PubMed PubMed Central Google Scholar
• Marino, M. J. et al. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc. Natl Acad. Sci. USA 100, 13668–13673 (2003). Discovery of a novel mGluR4 PAM and demonstration that this compound has anti-parkinsonian activity in animal models.
  CAS PubMed PubMed Central Google Scholar
• Niswender, C. M. et al. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol. Pharmacol. 74, 1345–1358 (2008).
  CAS PubMed Google Scholar
• Maj, M. et al. (−)-PHCCC, a positive allosteric modulator of mGluR4: characterization, mechanism of action, and neuroprotection. Neuropharmacology 45, 895–906 (2003).
  CAS PubMed Google Scholar
• Jones, P., Xiang, Z. & Conn, P. J. Metabotropic glutamate receptors mGluR4 and mGluR8 regulate transmission in the lateral olfactory tract-piriform. Neuropharmacol. (in the press).
• Valenti, O., Mannaioni, G., Seabrook, G. R., Conn, P. J. & Marino, M. J. Group III metabotropic glutamate-receptor-mediated modulation of excitatory transmission in rodent substantia nigra pars compacta dopamine neurons. J. Pharmacol. Exp. Ther. 313, 1296–1304 (2005).
  CAS PubMed Google Scholar
• Ayala, J. E., Niswender, C. M., Luo, Q., Banko, J. L. & Conn, P. J. Group III mGluR regulation of synaptic transmission at the SC-CA1 synapse is developmentally regulated. Neuropharmacol. 54, 804–814 (2008).
  CAS Google Scholar
• Battaglia, G. et al. Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. J. Neurosci. 26, 7222–7229 (2006).
  CAS PubMed PubMed Central Google Scholar
• Mathiesen, J. M., Svendsen, N., Brauner-Osborne, H., Thomsen, C. & Ramirez, M. T. Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP. Br. J. Pharmacol. 138, 1026–1030 (2003).
  CAS PubMed PubMed Central Google Scholar
• Wess, J., Eglen, R. M. & Gautam, D. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development. Nature Rev. Drug Discov. 6, 721–733 (2007).
  CAS Google Scholar
• Clader, J. W. & Wang, Y. Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease. Curr. Pharm. Des 11, 3353–3361 (2005).
  CAS PubMed Google Scholar
• Bymaster, F. P., Felder, C., Ahmed, S. & McKinzie, D. Muscarinic receptors as a target for drugs treating schizophrenia. Curr. Drug Targets. CNS Neurol. Disord. 1, 163–181 (2002).
  CAS PubMed Google Scholar
• Shekhar, A. et al. Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am. J. Psychiatry 165, 1033–1039 (2008).
  PubMed Google Scholar
• Greenlee, W. et al. Muscarinic agonists and antagonists in the treatment of Alzheimer's disease. Farmaco 56, 247–250 (2001).
  CAS PubMed Google Scholar
• Langmead, C. J. et al. Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28–21 Br. J. Pharmacol. 154, 1104–1115 (2008).
  CAS PubMed PubMed Central Google Scholar
• Spalding, T. A. et al. Discovery of an ectopic activation site on the M(1) muscarinic receptor. Mol. Pharmacol. 61, 1297–1302 (2002).
  CAS PubMed Google Scholar
• Sur, C. et al. N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc. Natl Acad. Sci. USA 100, 13674–13679 (2003).
  CAS PubMed PubMed Central Google Scholar
• Lazareno, S. et al. Allosteric effects of four stereoisomers of a fused indole ring system with 3H-N-methylscopolamine and acetylcholine at M1-M4 muscarinic receptors. Life Sci. 64, 519–26 (1999).
  CAS PubMed Google Scholar
• Jones, C. K. et al. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor reduces amyloid processing and produces antipsychotic-like activity in rats. J. Neurosci. (in the press).
• Chan, W. Y. et al.Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc. Natl Acad. Sci. USA (in the press).
• Shirey, J. K. et al. An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nature Chem. Biol. 4, 42–50 (2008). Together with reference 104, important studies identifying allosteric modulation of the M 4 muscarinic receptor as a novel approach for the treatment of CNS disorders.
  CAS Google Scholar
• Brady, A. et al. Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotion behavior in rats. J. Pharmacol. Exp. Ther. (in the press).
• Nawaratne, V. et al. New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug). Mol. Pharmacol. 74, 1119–1131 (2008).
  CAS PubMed Google Scholar
• Black, J. W. & Leff, P. Operational models of pharmacological agonism. Proc. R. Soc. Lond. B Biol. Sci. 220, 141–162 (1983).
  CAS PubMed Google Scholar
• Kenakin, T. Allosteric agonist modulators. J. Recept Signal Transduct. Res. 27, 247–259 (2007).
  CAS PubMed Google Scholar
• Gether, U. & Kobilka, B. K. G protein-coupled receptors. II. Mechanism of agonist activation. J. Biol. Chem. 273, 17979–17982 (1998).
  CAS PubMed Google Scholar
• Leppik, I. E. Antiepileptic drugs in development: prospects for the near future. Epilepsia 35, Suppl 4, 29–40 (1994).
  Google Scholar
• Matsui, H., Lazareno, S. & Birdsall, N. J. Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis. Mol. Pharmacol. 47, 88–98 (1995).
  CAS PubMed Google Scholar
• Gnagey, A. L., Seidenberg, M. & Ellis, J. Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors. Mol. Pharmacol. 56, 1245–1253 (1999).
  CAS PubMed Google Scholar
• Krejci, A. & Tucek, S. Changes of cooperativity between N-methylscopolamine and allosteric modulators alcuronium and gallamine induced by mutations of external loops of muscarinic M(3) receptors. Mol. Pharmacol. 60, 761–767 (2001).
  CAS PubMed Google Scholar
• Buller, S., Zlotos, D. P., Mohr, K. & Ellis, J. Allosteric site on muscarinic acetylcholine receptors: a single amino acid in transmembrane region 7 is critical to the subtype selectivities of caracurine V derivatives and alkane-bisammonium ligands. Mol. Pharmacol. 61, 160–168 (2002).
  CAS PubMed Google Scholar
• Voigtlander, U. et al. Allosteric site on muscarinic acetylcholine receptors: identification of two amino acids in the muscarinic M2 receptor that account entirely for the M2/M5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors. Mol. Pharmacol. 64, 21–31 (2003).
  PubMed Google Scholar
• Huang, X. P., Prilla, S., Mohr, K. & Ellis, J. Critical amino acid residues of the common allosteric site on the M2 muscarinic acetylcholine receptor: more similarities than differences between the structurally divergent agents gallamine and bis(ammonio)alkane-type hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide. Mol. Pharmacol. 68, 769–778 (2005).
  CAS PubMed Google Scholar
• Prilla, S., Schrobang, J., Ellis, J., Holtje, H. D. & Mohr, K. Allosteric interactions with muscarinic acetylcholine receptors: complex role of the conserved tryptophan M2422Trp in a critical cluster of amino acids for baseline affinity, subtype selectivity, and cooperativity. Mol. Pharmacol. 70, 2181–2193 (2006).
  Google Scholar
• Avlani, V., May, L. T., Sexton, P. M. & Christopoulos, A. Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 308, 1062–1072 (2004).
  CAS PubMed Google Scholar
• Jakubik, J., Krejci, A. & Dolezal, V. Asparagine, valine, and threonine in the third extracellular loop of muscarinic receptor have essential roles in the positive cooperativity of strychnine-like allosteric modulators. J. Pharmacol. Exp. Ther. 313, 688–696 (2005).
  CAS PubMed Google Scholar
• Liaw, C. W., Grigoriadis, D. E., Lorang, M. T., De Souza, E. B. & Maki, R. A. Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. Mol. Endocrinol. 11, 2048–2053 (1997).
  CAS PubMed Google Scholar
• Dragic, T. et al. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl Acad. Sci. USA 97, 5639–5644 (2000).
  CAS PubMed PubMed Central Google Scholar
• Gerlach, L. O., Skerlj, R. T., Bridger, G. J. & Schwartz, T. W. Molecular interactions of cyclam and bicyclam non-peptide antagonists with the CXCR4 chemokine receptor. J. Biol. Chem. 276, 14153–14160 (2001).
  CAS PubMed Google Scholar
• Tsamis, F. et al. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J. Virol. 77, 5201–5208 (2003).
  CAS PubMed PubMed Central Google Scholar
• Rosenkilde, M. M. et al. Molecular mechanism of AMD3100 antagonism in the CXCR4 receptor: transfer of binding site to the CXCR3 receptor. J. Biol. Chem. 279, 3033–3041 (2004).
  CAS PubMed Google Scholar
• Maeda, K. et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J. Virol. 78, 8654–8662 (2004).
  CAS PubMed PubMed Central Google Scholar
• Maeda, K. et al. Structural and molecular interactions of CCR5 inhibitors with CCR5. J. Biol. Chem. 281, 12688–12698 (2006).
  CAS PubMed Google Scholar
• Hemstapat, K., de Paulis, T., Chen, Y., Brady, A. E., Grover, V. K., Alagille, D., Tamagnan, G. D., Conn, P. J. A novel class of positive allosteric modulators of mGluR1 interact with a site distinct from that of negative allosteric modulators. Mol. Pharmacol. 70, 616–626 (2006).
  CAS PubMed Google Scholar
• Dupuis, D. S., Relkovic, D., Lhuillier, L., Mosbacher, J. & Kaupmann, K. Point mutations in the transmembrane region of GABAB2 facilitate activation by the positive modulator N, N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4, 6-diamine (GS39783) in the absence of the GABAB1 subunit. Mol. Pharmacol. 70, 2027–2036 (2006).
  CAS PubMed Google Scholar
• Pagano, A. et al. The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J. Biol. Chem. 275, 33750–33758 (2000).
  CAS PubMed Google Scholar
• Knoflach, F. et al. Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc. Natl Acad. Sci. USA 98, 13402–13407 (2001).
  CAS PubMed PubMed Central Google Scholar
• Baez, M. et al. Molecular mapping of a subtype selective site for positive allosteric modulation of the mGlu2 receptor. Neuropharmacol. Abstr. 43, 274–275 (2002).
  Google Scholar
• Malherbe, P. et al. Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor. J. Biol. Chem. 278, 8340–8347 (2003).
  CAS PubMed Google Scholar
• Petrel, C. et al. Modeling and mutagenesis of the binding site of Calhex 231, a novel negative allosteric modulator of the extracellular Ca(2+)-sensing receptor. J. Biol. Chem. 278, 49487–49494 (2003).
  CAS PubMed Google Scholar
• Miedlich, S. U., Gama, L., Seuwen, K., Wolf, R. M. & Breitwieser, G. E. Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site. J. Biol. Chem. 279, 7254–7263 (2004).
  CAS PubMed Google Scholar
• Binet, V. et al. The heptahelical domain of GABA(B2) is activated directly by CGP7930, a positive allosteric modulator of the GABA(B) receptor. J. Biol. Chem. 279, 29085–29091 (2004).
  CAS PubMed Google Scholar